Autologous Graft versus Host Disease: An Emerging Complication in Patients with Multiple Myeloma

Table 1

MM patient characteristics.

Characteristic	AutoGVHD; Number (n = 8)	Non-autoGVHD; Number (n = 16)
Age, years
Mean ± SD	60 ± 5.3	62.1 ± 7.8
Range	51–66	42–71
Sex
% male	62.5	37.5
Race, number
Caucasian	7	15
African American	0	1
Hispanic	1	0
Mobilization, number
G	0	2
DTPACE + G	1	1
BDTPACE + G	3	5
MBDTPACE + G	3	5
DTPACE + pegG/DA	1	0
BDTPACE + PL + G	0	3
Autologous HPC transplant, number
Mean ± SD	2.1 ± 0.8	1.6 ± 0.7

A: adriamycin; B: bortezomib; C: cyclophosphamide; D: dexamethasone; DA: darbepoetin alfa; E: etoposide; G: granulocyte-colony stimulating factor; M: melphalan; P: cisplatin; PL: plerixafor; SD: standard deviation; T: thalidomide.